CBLL Quote, Financials, Valuation and Earnings

Boston Scientific Corp. has a net margin of -59.61% compared to Ceribell, Inc.'s net margin of 14.91%. Ceribell, Inc.'s return on equity of -36.45% beat Boston Scientific Corp.'s return on equity of 12.46%.

Ceribell, Inc. has a consensus price target of $28.14, signalling upside risk potential of 33.44%. On the other hand Boston Scientific Corp. has an analysts' consensus of $125.86 which suggests that it could grow by 30.52%. Given that Ceribell, Inc. has higher upside potential than Boston Scientific Corp., analysts believe Ceribell, Inc. is more attractive than Boston Scientific Corp..

Ceribell, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Boston Scientific Corp. has a beta of 0.673, suggesting its less volatile than the S&P 500 by 32.691%.

Ceribell, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ceribell, Inc. pays -- of its earnings as a dividend. Boston Scientific Corp. pays out -- of its earnings as a dividend.

Ceribell, Inc. quarterly revenues are $22.6M, which are smaller than Boston Scientific Corp. quarterly revenues of $5.1B. Ceribell, Inc.'s net income of -$13.5M is lower than Boston Scientific Corp.'s net income of $755M. Notably, Ceribell, Inc.'s price-to-earnings ratio is -- while Boston Scientific Corp.'s PE ratio is 51.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ceribell, Inc. is 9.31x versus 7.41x for Boston Scientific Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Perspective Therapeutics, Inc. has a net margin of -59.61% compared to Ceribell, Inc.'s net margin of -12425.36%. Ceribell, Inc.'s return on equity of -36.45% beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.

Ceribell, Inc. has a consensus price target of $28.14, signalling upside risk potential of 33.44%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.3077 which suggests that it could grow by 331.85%. Given that Perspective Therapeutics, Inc. has higher upside potential than Ceribell, Inc., analysts believe Perspective Therapeutics, Inc. is more attractive than Ceribell, Inc..

Ceribell, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.222, suggesting its more volatile than the S&P 500 by 22.249%.

Ceribell, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ceribell, Inc. pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.

Ceribell, Inc. quarterly revenues are $22.6M, which are larger than Perspective Therapeutics, Inc. quarterly revenues of $209K. Ceribell, Inc.'s net income of -$13.5M is higher than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, Ceribell, Inc.'s price-to-earnings ratio is -- while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ceribell, Inc. is 9.31x versus 184.77x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Electromed, Inc. has a net margin of -59.61% compared to Ceribell, Inc.'s net margin of 12.65%. Ceribell, Inc.'s return on equity of -36.45% beat Electromed, Inc.'s return on equity of 18.89%.

Ceribell, Inc. has a consensus price target of $28.14, signalling upside risk potential of 33.44%. On the other hand Electromed, Inc. has an analysts' consensus of $36.00 which suggests that it could grow by 31.63%. Given that Ceribell, Inc. has higher upside potential than Electromed, Inc., analysts believe Ceribell, Inc. is more attractive than Electromed, Inc..

Ceribell, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Electromed, Inc. has a beta of 0.259, suggesting its less volatile than the S&P 500 by 74.113%.

Ceribell, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ceribell, Inc. pays -- of its earnings as a dividend. Electromed, Inc. pays out -- of its earnings as a dividend.

Ceribell, Inc. quarterly revenues are $22.6M, which are larger than Electromed, Inc. quarterly revenues of $16.9M. Ceribell, Inc.'s net income of -$13.5M is lower than Electromed, Inc.'s net income of $2.1M. Notably, Ceribell, Inc.'s price-to-earnings ratio is -- while Electromed, Inc.'s PE ratio is 29.42x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ceribell, Inc. is 9.31x versus 3.65x for Electromed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings, Inc. has a net margin of -59.61% compared to Ceribell, Inc.'s net margin of 3.93%. Ceribell, Inc.'s return on equity of -36.45% beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.

Ceribell, Inc. has a consensus price target of $28.14, signalling upside risk potential of 33.44%. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 92.31%. Given that Xtant Medical Holdings, Inc. has higher upside potential than Ceribell, Inc., analysts believe Xtant Medical Holdings, Inc. is more attractive than Ceribell, Inc..

Ceribell, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.052, suggesting its less volatile than the S&P 500 by 105.153%.

Ceribell, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ceribell, Inc. pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.

Ceribell, Inc. quarterly revenues are $22.6M, which are smaller than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. Ceribell, Inc.'s net income of -$13.5M is lower than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, Ceribell, Inc.'s price-to-earnings ratio is -- while Xtant Medical Holdings, Inc.'s PE ratio is 76.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ceribell, Inc. is 9.31x versus 0.85x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.